⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12284250 | 0.74 | L3MBTL1 (0.35) | — | |
| SCHEMBL16840852 | 0.74 | HTT (0.34) | — | |
| SCHEMBL16817568 | 0.74 | — | — | |
| SCHEMBL3796925 | 0.72 | — | — | |
| SCHEMBL13878111 | 0.71 | — | — | |
| SCHEMBL1170174 | 0.70 | — | — | |
| SCHEMBL12378572 | 0.70 | — | — | |
| SCHEMBL2288930 | 0.70 | — | — | |
| SCHEMBL10146608 | 0.68 | L3MBTL1 (0.32) | — | |
| SCHEMBL991159 | 0.68 | CHRM2 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12024525-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | AGENEBIO, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-12024525-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | AGENEBIO, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| EP-3555100-B1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO INC (US) | 2023-05-10 | — | — | EP | disclosed |
| US-20230134844-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230134844-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO, INC. | 2023-05-04 | — | — | US | disclosed |
| EP-3083569-B1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO INC (US) | 2022-01-26 | — | — | EP | disclosed |
| US-11142529-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | AGENEBIO, INC. (US) | 2021-10-12 | — | — | US | disclosed |
| US-20210253588-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO, INC. | 2021-08-19 | — | — | US | disclosed |
| US-10815242-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | AGENEBIO, INC. (US) | 2020-10-27 | — | — | US | disclosed |
| US-20200048268-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-02-13 | — | — | US | disclosed |
| US-20190284196-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | HAGER BIOSCIENCES | 2019-09-19 | — | — | US | disclosed |
| US-10329301-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | AGENEBIO, INC. (US) | 2019-06-25 | — | — | US | disclosed |
| US-20190055258-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | HAGER BIOSCIENCES | 2019-02-21 | — | — | US | disclosed |
| WO-2018130869-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO, INC. (US) | 2018-07-19 | — | — | WO | disclosed |
| US-20180170941-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | HAGER BIOSCIENCES | 2018-06-21 | — | — | US | disclosed |
| US-20170253603-A2 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO, INC. (US) | 2017-09-07 | — | — | US | disclosed |
| US-20170253603-A2 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO, INC. (US) | 2017-09-07 | — | — | US | disclosed |
| US-20170022208-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO INC (US) | 2017-01-26 | — | — | US | disclosed |
| WO-2016205739-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | MEKONNEN BELEW (US) | 2016-12-22 | — | — | WO | disclosed |
| WO-2015095783-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO, INC. (US) | 2015-06-25 | — | — | WO | disclosed |